Oramed Pharmaceuticals (ORMP) Total Liabilities (2011 - 2026)

Oramed Pharmaceuticals has reported Total Liabilities for 16 years, with the latest figure at $30.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 299.88% year-over-year to $30.6 million; the trailing twelve-month figure through Mar 2026 stood at $30.6 million (up 299.88% YoY), and the FY2025 full-year result was $31.1 million, up 213.36% from the prior year.
• Total Liabilities for Q1 2026 stood at $30.6 million, down from $31.1 million in the prior quarter.
• The five-year high for Total Liabilities was $82.7 million in Q3 2023, with the low at $5.7 million in Q2 2023.
• Historically, Total Liabilities has averaged $21.0 million across 5 years, with a median of $10.0 million in 2022.
• Annual changes were most pronounced in 2023 — Total Liabilities jumped 632.18% — and 2024, when it tumbled 88.44%.
• Oramed Pharmaceuticals' Total Liabilities stood at $10.5 million in 2022, then surged by 449.86% to $57.7 million in 2023, then slumped by 82.78% to $9.9 million in 2024, then soared by 213.36% to $31.1 million in 2025, then fell by 1.76% to $30.6 million in 2026.
• The last three Total Liabilities figures came in at $30.6 million (Q1 2026), $31.1 million (Q4 2025), and $18.2 million (Q3 2025), per Business Quant data.